BIO-GENE TECHNOLOGY LTD

Quarterly Activities Report and Appendix 4C

For quarter ended 31 December 2025 (Q2 FY26)

Q2 FY26 Highlights

- **Bio-Gene enters 2026 with momentum across Flavocide® and Qcide® platforms, having moved during 2025 from foundational development into more advanced regulatory, product development, and commercialisation activities**

- **Progress for the US Department of Defense grant programs:**
    - **Flavocide® wearable device project is progressing through device engineering and formulation development**
    - **Qcide® indoor spray project is pending initiation following lifting of US Government shutdown and finalisation of agreements with US partners**

- **Qcide® has been approved by the US Organic Materials Review Institute (OMRI) for listing as a Botanical Pesticide under the USDA National Organic Program in the OMRI Products List**

Bio-Gene Technology Limited (**ASX:BGT**, "**Bio-Gene**" or "**the Company**"), an Australian agtech company developing the next generation of novel insecticides derived from nature, provides an update on activities for the quarter ended 31 December 2025 (Q2 FY26) and to date.

Tim Grogan, Managing Director & CEO comments on recent progress and the outlook for the year ahead:

"Bio-Gene has started 2026 with strong momentum across both of our proprietary insecticidal platforms, Flavocide® and Qcide®, as we have moved during 2025 into more advanced regulatory, product development and commercialisation activities.

"For Flavocide®, the near-term focus will be on completing the suite of regulatory-enabling safety studies required to support our future applications for registrations in multiple jurisdictions. These studies are being conducted following guidance received from the Australian regulator and are designed to build a robust, globally relevant data package to underpin commercial deployment.

In parallel, we will continue our formulation development activities with our commercial partners and expand the data supporting Flavocide's efficacy across our target markets. Our pilot-scale manufacturing success with Rallis India has also provided us with a clear path to scale-up Flavocide®, placing us in a stronger position to support future supply arrangements with our current and future commercial partners.

"We will continue to move Qcide® forward in both production and market-access. Ongoing work in Far North Queensland to improve yields, plantation performance and biomass processing has been extremely pleasing and is strengthening the capacity for long-term production of Qcide®. At the same time, we will look to expand Qcide®'s regulatory and certification pathways following our recent OMRI listing in the United States, which supports our positioning in organic and sustainable agriculture markets and creates a foundation for additional Qcide®-based formulations.

"Commercial engagement across both platforms is expected to broaden further, building on existing collaborations with major global companies in major categories, including public health, crop protection and consumer pest control. These partnerships not only provide validation of our technology but also ensure that formulation development and product positioning are closely aligned with real-world market requirements.

"We also continue to benefit from strong external validation and grant funding through our US Department of Defense programs. Through these programs we are developing a Flavocide®-based wearable mosquito protection device and a Qcide® indoor spray for public health pests. These projects are expected to generate valuable technical and performance data over the coming year and to also demonstrate the versatility of Bio-Gene's natural insecticide platform.

"With a refreshed and focused pipeline of eight active product opportunities, expanding international business development activity and growing demand for safer, biologically derived pest control solutions, we are well positioned to deliver further technical, regulatory and commercial milestones over the year ahead."

Bio-Gene advances two US Department of Defense-funded programs

In December 2025, Bio-Gene provided an update on its two US Department of Defense Deployed Warfighter Protection (DWFP) programs, which are being supported by A$3.0 million (US$1.9 million) in competitive grant funding over three years to develop new insect-control solutions aimed at protecting military personnel and civilian populations from insect-borne diseases.

The first program is focused on developing a wearable device incorporating Bio-Gene's Flavocide® insecticide to protect against flying insect vectors such as mosquitoes. The project is progressing in line with its original development plan, with work well underway on both device engineering and formulation development in collaboration with the US company GearJump Technologies and a number of US military and agricultural research institutions. With this foundation in place, initial entomological testing has begun, and early small-cage trials have demonstrated evidence of mosquito mortality. These results indicate that the wearable "emanator" concept is functioning as intended at this early stage and provides early validation of the platform.

The second program is centered on the development of a Qcide®-based indoor residual spray designed to control bed bugs, resting houseflies and other crawling pests in indoor environments. This project is pending formal commencement following the lifting of the recent US Government shutdown and the finalisation of agreements with US research partners. Workstreams are being put in place to enable laboratory testing of prototype formulations, with the first studies, focused on houseflies, to commence in early 2026.

Key US organic approval for Qcide® secured

During the quarter, Bio-Gene announced that its natural insecticide Qcide® has been approved by the US-based Organic Materials Review Institute (OMRI) for listing under the USDA National Organic Program, allowing it to be used in certified organic production systems. Qcide®, which is derived from *Eucalyptus cloeziana* and produced via steam distillation, was accepted by OMRI as a 100% natural, non-synthetic botanical pesticide with no restrictions on composition or purity.

The OMRI listing confirms Qcide® meets US organic standards for crop pest, weed and disease control and enables Bio-Gene to market the product using the OMRI Listed® seal once regulatory approvals for use are in place. While OMRI listing is not itself an organic certification or regulatory approval, it allows Qcide® to be incorporated into certified organic farming systems, subject to standard USDA organic pest-management rules.

Strategically, the approval expands the potential commercial reach of Qcide® across organic agriculture, eco-label consumer products, crop protection and public-health pest control markets. It also establishes a pathway for future OMRI listings of Qcide®-based formulated products and supports Bio-Gene's strategy of developing environmentally responsible, nature-derived insect control solutions in markets with rising demand for sustainable alternatives.

Financial update - R&D tax incentive

In November, the Company received a research and development tax incentive (RDTI) of $519,500 from the Australian Taxation Office. The cash incentive related to R&D expenditure incurred by the Company in the 2025 financial year.

The RDTI is an Australian Federal Government program under which companies can receive cash incentives for 43.5% of eligible R&D expenditure. The RDTI relates to both Australian and eligible overseas expenditure for the development of the Company's products Flavocide® and Qcide®.

Approved for release by the Board of Directors.

- ENDS -

For further information, please contact:

Bio-Gene Technology Limited:
E: bgt.info@bio-gene.com.au

Matthew Wright, NWR Communications
E: matt@nwrcommunications.com.au
M: 0451 896 420

About Bio-Gene Technology Limited

Bio-Gene is an Australian company developing novel bio-insecticides to address the global challenges of insecticide resistance and toxicity. Its unique products are based on a naturally occurring class of compounds proven to overcome resistance to control pests with minimal impact on human health and the environment.

Bio-Gene's products have multiple applications across public health, crop protection, grain storage, and consumer use. They provide new options derived from nature to meet market demand for effective and safe pest management solutions.

Flavocide® and Qcide® are registered trademarks of Bio-Gene Technology Limited in Australia.

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

Bio-Gene Technology Limited

ABN	**Quarter ended ("current quarter")**
32 071 735 950	**31 December 2025**

Consolidated statement of cash flows		**Current quarter $A'000**	**Year to date $A'000**
1.	**Cash flows from operating activities**		
1.1	Receipts from Tax Incentive	707	814
1.2	Payments for		
	(a) commercialisation expenses	(174)	(252)
	(b) research and development	(551)	(1,049)
	(c) intellectual property	(52)	(103)
	(d) professional services	(13)	(29)
	(e) directors' expenses	(47)	(94)
	(f) administration and corporate costs (see note 6)	(143)	(248)
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	6	15
1.5	Interest and other costs of finance paid	-	-
1.6	Income taxes paid	-	-
1.7	Government grants and tax incentives	-	-
1.8	Other (provide details if material)	-	-
1.9	**Net cash from / (used in) operating activities**	**(267)**	**(946)**

2.	**Cash flows from investing activities**		
2.1	Payments to acquire or for:	-	-
	(a) entities		
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	**Net cash from / (used in) investing activities**	**-**	**-**

3.	**Cash flows from financing activities**		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	965
3.2	Proceeds from issue of convertible debt securities		
3.3	Proceeds from exercise of options		
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	(25)
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	(51)
3.7	Transaction costs related to loans and borrowings		
3.8	Dividends paid		
3.9	Other (share proceeds received in advance)		
3.10	**Net cash from / (used in) financing activities**	**-**	**889**

4.	**Net increase / (decrease) in cash and cash equivalents for the period**		
4.1	Cash and cash equivalents at beginning of period	1,348	1,138
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(267)	(946)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	-	-
4.4	Net cash from / (used in) financing activities (item 3.10 above)	-	889
4.5	Effect of movement in exchange rates on cash held	-	-
4.6	**Cash and cash equivalents at end of period**	**1,081**	**1,081**

5.	**Reconciliation of cash and cash equivalents** at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	**Current quarter $A'000**	**Previous quarter $A'000**
5.1	Bank balances	80	95
5.2	Call deposits	701	653
5.3	Bank overdrafts	-	-
5.4	Other (Term Deposits)	300	600
5.5	**Cash and cash equivalents at end of quarter (should equal item 4.6 above)**	**1,081**	**1,348**

6.	**Payments to related parties of the entity and their associates**	**Current quarter $A'000**
6.1	Aggregate number of payments to related parties and their associates included in item 1	94
6.2	Aggregate number of payments to related parties and their associates included in item 2	N/A

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.

Note 6.1: Director's fees paid to Directors or their related entities plus remuneration paid to Executive Directors.

7.	**Financing facilities** *Note: the term "facility' includes all forms of financing arrangements available to the entity.* *Add notes as necessary for an understanding of the sources of finance available to the entity.*	**Total facility amount at quarter end $A'000**	**Amount drawn at quarter end $A'000**
7.1	Loan facilities	N/A	N/A
7.2	Credit standby arrangements	N/A	N/A
7.3	Other (please specify)	N/A	N/A
7.4	**Total financing facilities**	**N/A**	**N/A**
7.5	**Unused financing facilities available at quarter end**		**N/A**
7.6	Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.		

8.	**Estimated cash available for future operating activities**	**$A'000**
8.1	Net cash from / (used in) operating activities (item 1.9)	(267)
8.2	Cash and cash equivalents at quarter end (item 4.6)	1,081
8.3	Unused finance facilities available at quarter end (item 7.5)	-
8.4	Total available funding (item 8.2 + item 8.3)	**1,081**
8.5	**Estimated quarters of funding available (item 8.4 divided by item 8.1)**	4.04
	Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.	

8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:

8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer:

8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer:

8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer:

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

Compliance statement

1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

2 This statement gives a true and fair view of the matters disclosed.

Date: 30 January 2026

Authorised by: The Board of Directors

(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [*name of board committee – e.g. Audit and Risk Committee*]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.
6. Net movements in GST are included in this item.
7. Prior Quarter Corrections. Immaterial minor errors and reallocations of expenses from previous quarter reports are corrected on a year-to-date basis. Movements disclosed for the current quarter have been correctly calculated.